Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial.

Journal Article (Journal Article)

Multigene assays can provide insight into key biological processes and prognostic information to guide development and selection of adjuvant cancer therapy. We report a comprehensive genomic and transcriptomic analysis of tumor samples from 171 patients at high risk for recurrent renal cell carcinoma post nephrectomy from the S-TRAC trial (NCT00375674). We identify gene expression signatures, including STRAC11 (derived from the sunitinib-treated population). The overlap in key elements captured in these gene expression signatures, which include genes representative of the tumor stroma microenvironment, regulatory T cell, and myeloid cells, suggests they are likely to be both prognostic and predictive of the anti-angiogenic effect in the adjuvant setting. These signatures also point to the identification of potential therapeutic targets for development in adjuvant renal cell carcinoma, such as MERTK and TDO2. Finally, our findings suggest that while anti-angiogenic adjuvant therapy might be important, it may not be sufficient to prevent recurrence and that other factors such as immune response and tumor environment may be of greater importance.

Full Text

Duke Authors

Cited Authors

  • Motzer, RJ; Martini, J-F; Mu, XJ; Staehler, M; George, DJ; Valota, O; Lin, X; Pandha, HS; Ching, KA; Ravaud, A

Published Date

  • October 10, 2022

Published In

Volume / Issue

  • 13 / 1

Start / End Page

  • 5959 -

PubMed ID

  • 36216827

Pubmed Central ID

  • PMC9550765

Electronic International Standard Serial Number (EISSN)

  • 2041-1723

Digital Object Identifier (DOI)

  • 10.1038/s41467-022-33555-8


  • eng

Conference Location

  • England